Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma.

Trial Profile

Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs BC 819 (Primary) ; BC 819 (Primary) ; BCG; BCG
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 01 Oct 2015 Results published in BioCancell media release.
    • 25 Mar 2014 According to ClinicalTrials.gov record study design changed from randomized to non-randomized; number of patients increased from 12 to 18; and an additional arm group (BC-819 + BCG ) is added.
    • 25 Mar 2014 Planned number of patients changed from 12 to 18 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top